drugset / Trial / NCT04138251

Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency

NCT04138251

NaSingle-groupOpen-labelTreatment

Summary

Treatment of neutropenia of G6PC3 and Glycogenosis type 1b patients with empagliflozin

Timeline

Start
2019-06-20
Primary completion
2020-06-30
Completion
2020-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 10 mg Oral